Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT01115439
Other study ID # BAKMAL1002
Secondary ID
Status Completed
Phase N/A
First received March 29, 2010
Last updated July 11, 2012
Start date March 2010
Est. completion date July 2011

Study information

Verified date July 2012
Source University of Oxford
Contact n/a
Is FDA regulated No
Health authority Afghanistan: Ministry of Public Health
Study type Observational

Clinical Trial Summary

In Afghanistan, studies over the past 15 years have shown a high degree of Plasmodium falciparum resistance to chloroquine (80%) and more recently an increasing degree of resistance to sulfadoxine-pyrimethamine monotherapy (12%). In 2003 the high failure rate of chloroquine against falciparum malaria led the national malaria treatment programme to switch its recommended first line drug treatment for uncomplicated Plasmodium falciparum malaria to artemisinin-based combination therapy (ACT) in the form of Artesunate/Sulfadoxine-Pyrimethamine (AS+SP). Second line drug treatment is oral quinine (7 days). The aim of this study is to conduct ongoing monitoring of the efficacy of the new combination against P. falciparum in a group of sentinel sites in Afghanistan.


Description:

The objective of the study is to assess the efficacy and safety of Artesunate/Sulfadoxine-Pyrimethamine (AS+SP) for the treatment of uncomplicated P. falciparum infections in Nangarhar, Kunar, Thakhar, Faryab malaria control centers in Afghanistan.

This is an observational study. Patients will receive the recommended treatment for P. falciparum malaria in Afghanistan (Nangarhar, Kunar, Thakhar, Faryab malaria control centers). The participants will be febrile children above six months of age and non-pregnant adults with confirmed uncomplicated P. falciparum infection. Patients will be treated with AS+SP according to standard dosing regimens. Clinical and parasitological parameters will be monitored over a 42-day follow-up period to evaluate drug efficacy. The study will be conducted during the transmission season of falciparum malaria, i.e. October 2009 to January 2010 and September-December, 2010. Patients will be assessed clinically and via laboratory tests, particularly focussing on whether recurrences are recrudescences of the original infection or reinfections. All bio-medical findings will be recorded in specific patient case record forms and the electronic form of analyzed data as well as a final report will be sent to WHO-Afghanistan and National malaria control program offices for further actions. The patients will receive reasonable transportation costs for follow-up visits as well as one insecticide treated bed-net at the end of enrolment. The results of this study will be used to assist the Ministry of Health of Afghanistan in assessing the current national treatment guidelines for uncomplicated P. falciparum malaria.


Recruitment information / eligibility

Status Completed
Enrollment 100
Est. completion date July 2011
Est. primary completion date April 2011
Accepts healthy volunteers No
Gender Both
Age group 6 Months and older
Eligibility Inclusion:

- Age over six months.

- Mono-infection with P. falciparum detected by microscopy at a level of 500-150,000/µL asexual forms

- Presence of axillary or tympanic temperature = 37.5 °C or oral or rectal temperature of = 38 °C or history of fever during the past 24 h;

- ability to swallow oral medication;

- ability and willingness to comply with the study protocol for the duration of the study and to comply with the study visit schedule; and

- Informed consent from the patient or from a parent or guardian in the case of children under 18 years of age.

Exclusion criteria:

- Presence of general danger signs in children aged under 5 years or signs of severe falciparum malaria according to the definitions of the World Health Organization (WHO)

- Mixed or mono-infection with another Plasmodium species detected by microscopy

- Presence of severe malnutrition (defined as a child whose growth standard is below -3 z-score, has symmetrical oedema involving at least the feet or has a mid-upper arm circumference < 110 mm)

- Presence of febrile conditions due to diseases other than malaria (e.g. measles, acute lower respiratory tract infection, severe diarrhoea with dehydration) or other known underlying chronic or severe diseases (e.g. cardiac, renal and hepatic diseases, HIV/AIDS);

- Regular medication, which may interfere with antimalarial pharmacokinetics;

- History of hypersensitivity reactions or contraindications to any of the study medications;

- Female over 12 years of age

Study Design

Observational Model: Case-Only, Time Perspective: Prospective


Related Conditions & MeSH terms


Intervention

Drug:
artesunate plus sulfadoxine-pyrimethamine (AS+SP)
artesunate plus sulfadoxine-pyrimethamine (AS+SP)

Locations

Country Name City State
Afghanistan Provincial Malaria Control Centers (MRC) Asadabad Kunar
Afghanistan Provincial Malaria Control Centers (MRC) Jalalabad Nangarhar
Afghanistan Provincial Malaria Control Centers (MRC) Maimana Faryab
Afghanistan Provincial Malaria Control Centers (MRC) Taloqan

Sponsors (3)

Lead Sponsor Collaborator
University of Oxford National Malaria and Leishmaniasis Control Program, Afghanistan, World Health Organization

Country where clinical trial is conducted

Afghanistan, 

Outcome

Type Measure Description Time frame Safety issue
Primary Proportion of patients experiencing therapeutic failure Proportion of patients experiencing therapeutic failure 42 days No
See also
  Status Clinical Trial Phase
Completed NCT00440752 - The Impact of Artemether-Lumefantrine on Genes Associated With Antimalarial Resistance N/A
Completed NCT01144702 - Effectiveness of the Association Artesunate and Mefloquine in the Treatment of Malaria by Plasmodium Falciparum Phase 2/Phase 3
Terminated NCT00400101 - Phase Ia Malaria Vaccine Trial of Two Virosome-Formulated Peptides Phase 1
Completed NCT01350856 - Tracking Resistance to Artemisinin (TRAC) Phase 4
Completed NCT00859807 - A Bioequivalence Study Comparing Camoquin® Suspension (Pfizer) To Flavoquine® Tablets (Sanofi Aventis) In Healthy Subjects Phase 4
Completed NCT04222088 - TES of Artemether-lumefantrine for Pf and Chloroquine for Pv in the Philippines From 2013-2014
Completed NCT00282919 - A Three Day Trial of Azithromycin Plus Chloroquine for the Treatment of Uncomplicated Plasmodium Falciparum Malaria Phase 2
Completed NCT04422015 - Biological Mechanisms in Afebrile P. Falciparum Malaria
Completed NCT00894374 - Bioequivalence Study Comparing Artesunate Tablet To Arsuamoon® Tablets (Guilin-China) In Healthy Subjects Phase 1
Completed NCT00894660 - A Bioequivalence Study Comparing Amodiaquine Tablet (Pfizer) To Amodiaquine Tablets (Arsuamoon-Guilin China) In Healthy Subjects Phase 1
Completed NCT00493363 - Clinical Investigation of In-vivo Susceptibility of P.Falciparum to Artesunate in Western Cambodia N/A
Completed NCT00158548 - ACT With Chloroquine, Amodiaquine & Sulphadoxine-pyrimethamine in Pakistan Phase 3
Withdrawn NCT04289558 - Nitrite Infusion in Children With Malaria Phase 1
Completed NCT01374126 - Azithromycin Combination Therapy for the Treatment of Severe Malaria Phase 2
Completed NCT00722150 - Artemisinin Resistance in Cambodia II N/A
Completed NCT00157833 - A Randomized Trial of Coartemether and Artekin for the Treatment of Uncomplicated Malaria in Papua, Indonesia. N/A
Completed NCT00513669 - Phase Ib Trial of Two Virosome Formulated Malaria Vaccine Components (PEV 301, PEV 302) in Tanzania Phase 1
Completed NCT00403260 - Pyronaridine - Artesunate (3:1) Versus Mefloquine Plus Artesunate in Plasmodium Falciparum Malaria Patients Phase 3
Completed NCT00442377 - Study to Investigate the Induction of an Protective Immune Response to Malaria N/A
Completed NCT01365598 - Evaluation of the Gametocytocidal Efficacy and Safety of Primaquine in Uncomplicated Falciparum Malaria in Uganda Phase 3